Avantor, Inc. Cost of Revenue
Avantor, Inc. (AVTR) reported Cost of Revenue of $1.08 billion for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-04-29
- Avantor, Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $1.08B, a 3.27% increase year-over-year.
- Avantor, Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $1.14B, a 1.42% increase year-over-year.
- Avantor, Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $1.10B, a 4.58% decline year-over-year.
- Avantor, Inc. cost of goods and services sold for the quarter ending 2025-06-30 was $1.13B, a 0.71% increase year-over-year.
- Avantor, Inc. cost of goods and services sold for fiscal 2025 was $4.41B, a 2.03% decline from fiscal 2024.
- Avantor, Inc. cost of goods and services sold for fiscal 2024 was $4.50B, a 2.15% decline from fiscal 2023.
- Avantor, Inc. cost of goods and services sold for fiscal 2023 was $4.60B, a 6.24% decline from fiscal 2022.
- Avantor, Inc. cost of goods and services sold for fiscal 2022 was $4.91B, a 0.54% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-03-31 | $1.08B 10-Q · filed 2026-04-29 | $2.22B derived: sum of 2 quarters · filed 2026-04-29 | $3.32B derived: sum of 3 quarters · filed 2026-04-29 | $4.45B derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-12-31 | $1.14B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $2.24B derived: sum of 2 quarters · filed 2026-02-11 | $3.37B derived: sum of 3 quarters · filed 2026-02-11 | $4.41B 10-K · filed 2026-02-11 |
| 2025-09-30 | $1.10B 10-Q · filed 2025-10-29 | $2.23B derived: sum of 2 quarters · filed 2025-10-29 | $3.27B 10-Q · filed 2025-10-29 | $4.40B derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-06-30 | $1.13B 10-Q · filed 2025-08-01 | $2.18B 10-Q · filed 2025-08-01 | $3.30B derived: sum of 3 quarters · filed 2026-04-29 | $4.45B derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-03-31 | $1.05B 10-Q · filed 2026-04-29 | $2.17B derived: sum of 2 quarters · filed 2026-04-29 | $3.32B derived: sum of 3 quarters · filed 2026-04-29 | $4.44B derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $1.12B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $2.27B derived: sum of 2 quarters · filed 2026-02-11 | $3.40B derived: sum of 3 quarters · filed 2026-02-11 | $4.50B 10-K · filed 2026-02-11 |
| 2024-09-30 | $1.15B 10-Q · filed 2025-10-29 | $2.27B derived: sum of 2 quarters · filed 2025-10-29 | $3.38B 10-Q · filed 2025-10-29 | $4.53B derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $1.12B 10-Q · filed 2025-08-01 | $2.23B 10-Q · filed 2025-08-01 | $3.38B derived: sum of 3 quarters · filed 2026-02-11 | $4.52B derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $1.11B 10-Q · filed 2025-04-25 | $2.26B derived: sum of 2 quarters · filed 2026-02-11 | $3.40B derived: sum of 3 quarters · filed 2026-02-11 | $4.56B derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $1.15B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $2.29B derived: sum of 2 quarters · filed 2026-02-11 | $3.45B derived: sum of 3 quarters · filed 2026-02-11 | $4.60B 10-K · filed 2026-02-11 |
| 2023-09-30 | $1.14B 10-Q · filed 2024-10-25 | $2.30B derived: sum of 2 quarters · filed 2024-10-25 | $3.45B 10-Q · filed 2024-10-25 | $4.63B derived: sum of 4 quarters · filed 2025-02-07 |
| 2023-06-30 | $1.15B 10-Q · filed 2024-07-26 | $2.31B 10-Q · filed 2024-07-26 | $3.49B derived: sum of 3 quarters · filed 2025-02-07 | $4.70B derived: sum of 4 quarters · filed 2025-02-07 |
| 2023-03-31 | $1.16B 10-Q · filed 2024-04-26 | $2.34B derived: sum of 2 quarters · filed 2025-02-07 | $3.54B derived: sum of 3 quarters · filed 2025-02-07 | $4.80B derived: sum of 4 quarters · filed 2025-02-07 |
| 2022-12-31 | $1.18B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-07 | $2.39B derived: sum of 2 quarters · filed 2025-02-07 | $3.65B derived: sum of 3 quarters · filed 2025-02-07 | $4.91B 10-K · filed 2025-02-07 |
| 2022-09-30 | $1.21B 10-Q · filed 2023-10-27 | $2.47B derived: sum of 2 quarters · filed 2023-10-27 | $3.73B 10-Q · filed 2023-10-27 | $4.99B derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-30 | $1.26B 10-Q · filed 2023-07-28 | $2.52B 10-Q · filed 2023-07-28 | $3.78B derived: sum of 3 quarters · filed 2024-02-14 | $5.00B derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-03-31 | $1.26B 10-Q · filed 2023-04-28 | $2.52B derived: sum of 2 quarters · filed 2024-02-14 | $3.74B derived: sum of 3 quarters · filed 2024-02-14 | $4.97B derived: sum of 4 quarters · filed 2024-02-14 |
| 2021-12-31 | $1.26B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $2.48B derived: sum of 2 quarters · filed 2024-02-14 | $3.71B derived: sum of 3 quarters · filed 2024-02-14 | $4.88B 10-K · filed 2024-02-14 |
| 2021-09-30 | $1.22B 10-Q · filed 2022-10-28 | $2.45B derived: sum of 2 quarters · filed 2022-10-28 | $3.62B 10-Q · filed 2022-10-28 | $4.83B derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $1.23B 10-Q · filed 2022-07-29 | $2.40B 10-Q · filed 2022-07-29 | $3.61B derived: sum of 3 quarters · filed 2023-02-14 | $4.71B derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $1.17B 10-Q · filed 2022-04-29 | $2.38B derived: sum of 2 quarters · filed 2023-02-14 | $3.48B derived: sum of 3 quarters · filed 2023-02-14 | $4.47B derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $1.21B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $2.31B derived: sum of 2 quarters · filed 2023-02-14 | $3.30B derived: sum of 3 quarters · filed 2023-02-14 | $4.31B 10-K · filed 2023-02-14 |
| 2020-09-30 | $1.10B 10-Q · filed 2021-10-29 | $2.09B derived: sum of 2 quarters · filed 2021-10-29 | $3.10B 10-Q · filed 2021-10-29 | $4.15B derived: sum of 4 quarters · filed 2022-02-11 |
| 2020-06-30 | $988.10M 10-Q · filed 2021-07-30 | $2.01B 10-Q · filed 2021-07-30 | $3.05B derived: sum of 3 quarters · filed 2022-02-11 | $4.08B derived: sum of 4 quarters · filed 2022-02-11 |
| 2020-03-31 | $1.02B 10-Q · filed 2021-04-28 | $2.06B derived: sum of 2 quarters · filed 2022-02-11 | $3.09B derived: sum of 3 quarters · filed 2022-02-11 | $4.13B derived: sum of 4 quarters · filed 2022-02-11 |
| 2019-12-31 | $1.04B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-11 | $2.07B derived: sum of 2 quarters · filed 2022-02-11 | $3.11B derived: sum of 3 quarters · filed 2022-02-11 | $4.12B 10-K · filed 2022-02-11 |
| 2019-09-30 | $1.03B 10-Q · filed 2020-10-27 | $2.07B derived: sum of 2 quarters · filed 2020-10-27 | $3.08B 10-Q · filed 2020-10-27 | $4.12B derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-06-30 | $1.04B 10-Q · filed 2020-07-29 | $2.05B 10-Q · filed 2020-07-29 | $3.09B derived: sum of 3 quarters · filed 2021-02-16 | $4.10B derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-03-31 | $1.00B 10-Q · filed 2020-04-29 | $2.05B derived: sum of 2 quarters · filed 2021-02-16 | $3.06B derived: sum of 3 quarters · filed 2021-02-16 | $4.07B derived: sum of 4 quarters · filed 2021-02-16 |
| 2018-12-31 | $1.04B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $2.06B derived: sum of 2 quarters · filed 2021-02-16 | $3.07B derived: sum of 3 quarters · filed 2021-02-16 | $4.04B 10-K · filed 2021-02-16 |
| 2018-09-30 | $1.02B 10-Q · filed 2019-11-05 | $2.03B derived: sum of 2 quarters · filed 2019-11-05 | $3.00B 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $1.01B 10-Q · filed 2019-08-06 | $1.99B 10-Q · filed 2019-08-06 | ||
| 2017-12-31 | $814.60M 10-K · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRUKER CORP (BRKR) | United States | $9.706B | -128.75 |
| REVVITY, INC. (RVTY) | United States | $16.814B | 53.44 |
| Alamar Biosciences, Inc. (ALMR) | United States | $2.300B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |